Literature DB >> 24625203

Predicting menopausal age with anti-Müllerian hormone: a cross-validation study of two existing models.

F Ramezani Tehrani1, M Dólleman, J van Disseldorp, S L Broer, F Azizi, M Solaymani-Dodaran, B C Fauser, J S E Laven, M J C Eijkemans, F Broekmans.   

Abstract

OBJECTIVE: This study aimed to cross-validate two comparable Weibull models of prediction of age at natural menopause from two cohorts, the Scheffer, van Rooij, de Vet (SRV) cohort and the Tehran Lipid and Glucose Study (TLGS) cohort. It summarizes advantages and disadvantages of the models and underlines the need for achieving correct time dependency in dynamic variables like anti-Müllerian hormone.
METHODS: Models were fitted in the original datasets and then applied to the cross-validation datasets. The discriminatory capacity of each model was assessed by calculating C-statistics for the models in their own data and in the cross-validation data. Calibration of the models on the cross-validation data was assessed by measuring the slope, intercept and Weibull shape parameter.
RESULTS: The C-statistic for the SRV model on the SRV data was 0.7 (95% confidence interval (CI) 0.7-0.8) and on the TLGS data it was 0.8 (95% CI 0.8-0.9). For the TLGS model on the TLGS data, it was 0.9 (95% CI 0.8-0.9) and on the SRV data it was 0.7 (95% CI 0.6-0.8). After calibration of the SRV model on the TLGS data, the slope was 1, the intercept -0.3 and the shape parameter 1.1. The TLGS model on the SRV data had a slope of 0.3, an intercept of 12.7 and a shape parameter of 0.6.
CONCLUSIONS: Both models discriminate well between women that enter menopause early or late during follow-up. While the SRV model showed good agreement between the predicted risk of entering menopause and the observed proportion of women who entered menopause during follow-up (calibration) in the cross-validation dataset, the TLGS model showed poor calibration.

Entities:  

Keywords:  AGE AT MENOPAUSE; ANTI-MÜLLERIAN HORMONE; CROSS-VALIDATION STUDY; PREDICTION

Mesh:

Substances:

Year:  2014        PMID: 24625203     DOI: 10.3109/13697137.2014.898264

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  5 in total

Review 1.  Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Authors:  Akira Iwase; Tomoko Nakamura; Satoko Osuka; Sachiko Takikawa; Maki Goto; Fumitaka Kikkawa
Journal:  Reprod Med Biol       Date:  2015-11-23

2.  Association between a history of depression and anti-müllerian hormone among late-reproductive aged women: the Harvard study of moods and cycles.

Authors:  Samuel W Golenbock; Lauren A Wise; Geralyn M Lambert-Messerlian; Elizabeth E Eklund; Bernard L Harlow
Journal:  Womens Midlife Health       Date:  2020-09-01

3.  Back to the basics of ovarian aging: a population-based study on longitudinal anti-Müllerian hormone decline.

Authors:  A C de Kat; Y T van der Schouw; M J C Eijkemans; G C Herber-Gast; J A Visser; W M M Verschuren; F J M Broekmans
Journal:  BMC Med       Date:  2016-10-03       Impact factor: 8.775

4.  Maternal Exposure to D-galactose Reduces Ovarian Reserve in Female Rat Offspring Later in Life.

Authors:  Marzieh Rostami Dovom; Mahsa Noroozzadeh; Nariman Mosaffa; Abbas Piryaei; Azita Zadeh-Vakili; Mohammad-Amin Aabdollahifar; Maryam Rahmati; Mahbanoo Farhadi-Azar; Fahimeh Ramezani Tehrani
Journal:  Int J Endocrinol Metab       Date:  2022-05-30

Review 5.  Maximizing the clinical utility of antimüllerian hormone testing in women's health.

Authors:  Benjamin Leader; Valerie L Baker
Journal:  Curr Opin Obstet Gynecol       Date:  2014-08       Impact factor: 1.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.